EIM Group
http://www.eimgroup.com/jahia/page2.htmlEIM Group is a fund of fund that focuses on identifying, screening, and analyzing the best fund managers in different markets and investment styles.
View Older Stories View More Recent Stories
-
Eimskip: Annual Report 2022
-
LEIÐRÉTTING: VÍS: Reglubundin tilkynning um kaup á eigin bréfum í samræmi við endurkaupaáætlun
-
Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds
-
Eimskip: Candidates to the Board of Directors and 2023 AGM’s final agenda
-
Eimskip: AGM 2023 final agenda and proposals
-
Form 4 STREAMLINE HEALTH SOLUTI For: Feb 14 Filed by: Stilwill Benjamin Louis
-
Sjóvá: Reglubundin tilkynning um kaup á eigin bréfum í samræmi við endurkaupaáætlun
-
Eimskip: Annual General Meeting 9 March 2023
-
EIMSKIP: RESULT FOR THE YEAR 2022
-
Cognition Therapeutics, Inc. (CGTX) receives Notice of Allowance for its US patent related to AD
-
Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds
-
Docufree Wins 2022 Document Manager Award in "Enterprise CMS Product of the Year" Category
-
Disclosure of trading in own shares from January 16, 2023 to January 20, 2023
-
Eimskip: Major shareholder announcement from Stefnir
-
Eimskip: Information regarding Q4 results
-
Eimskip’s Nomination Committee is open for nominations
-
MorganFranklin Consulting Names Latest Class of New Leaders
-
Tilnefningarnefnd Sjóvár auglýsir eftir framboðum til stjórnar
-
Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds
-
Eimskip: Major shareholder announcement from Samherji Holding ehf. and A03 ehf.
-
Eimskip's Financial Calendar 2023
-
Frequency Electronics (FEIM) Declares $1.00 Special Dividend; 18.7% Yield
-
Nýr liðsfélagi í skemmtana- & framkvæmdastjórn Nova
-
Hexagon strengthens its physical security and incident management capabilities with the acquisition of Qognify
-
Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds
-
Neurosense Therapeutics (NRSN) Granted European Patent Related to Parkinson's and AD
-
Skel fjárfestingafélag hf.: Transaction of party closely associated with a board member
-
Eimskip: Results for Q3 2022
-
Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds
-
CORRECTING and REPLACING Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds
-
UNITY Biotechnology (UBX) Reports Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325
-
Hagar hf.: Reglubundin tilkynning um kaup Haga hf. á eigin bréfum í samræmi við endurkaupaáætlun
-
Docufree Acquires Document Intelligence Solution Provider DealerDOCX
-
Eimskip: Information regarding Q3 results
-
Eimskip: Transaction in relation to a share buy-back program – repurchase is completed
-
Alogent Extends its Leadership in the Enterprise Content & Information Management Market for Financial Institutions with the Acquisition of AccuSystems
-
Eimskip: Transaction in relation to a share buy-back program
-
Chicago Behavior Center Utilizes Innovative Virtual Reality to Treat Obsessive-Compulsive Disorder and Anxiety Disorders
-
Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds
-
Eimskip: Transaction in relation to a share buy-back program
-
VÍS: Tilkynning um framkvæmd endurkaupaáætlunar
-
Eimskip: Transaction in relation to a share buy-back program
-
Eimskip: Major shareholder announcement from LSR
-
Eimskip: Transaction in relation to a share buy-back program
-
Frequency Electronics (FEIM) Reports Q2 Loss of $0.33
-
Eimskip: Transaction in relation to a share buy-back program
-
Eimskip: Transaction in relation to a share buy-back program
-
Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds
-
Landos Biopharma (LABP) Granted U.S. Patent for Alzheimer's and Parkinson Treatment
-
Sjóvá: Reglubundin tilkynning um kaup á eigin bréfum í samræmi við endurkaupaáætlun

